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Abstract 
Finasteride is a potent inhibitor of the enzyme steroid 5a-reductase now approved as a drug for the treatment of 
benign prostatic hyperplasia. We describe an original method for the quantitative determination of finasteride at 
picogram level in human plasma by isotope-dilution gas chromatography mass spectrometry. 5,6,6-[2H3]Finasteride 
was synthesized with an high ratio of trideuteration (finasteride/[2H3]finasteride = 0.007) allowing its optimal use as 
internal standard. Plasma samples were purified in a single-step rocedure on solid-phase xtraction C~8 columns 
with a recovery />90%. Samples were injected in the GC-MS instrument without any derivatization and the 
minimum detection level of finasteride was 50 pg with a signal-to-noise ratio of 6:1. The coefficients of variation for 
the 5 and 10 ng/ml (plasma) concentrations were 5.8% and 4%, respectively. The method has been applied to the 
determination f the plasma pharmacokinetic of finasteride in five male volunteers treated with a single 5-mg dose 
of the drug, affording kinetic parameters which are in good agreement with the values previously reported with a 
different methodology. The present method results accurate, specific, sensible and reliable for a routinely 
determination f finasteride at picogram levels. 
Keywords: Isotope-dilution mass spectrometry; Finasteride 
L Introduction 
Finasteride (N-tert.-butyl-3-oxo-4-aza-androst- 
1-ene-17/3-carboxamide) is a 4-azasteroid syn- 
thesized by Merck Sharp & Dohme [1] that 
selectively inhibits steroid 5a-reductase, the en- 
zyme responsible of the conversion of testoster- 
one (T) into dihydrotestosterone (DHT).  The 
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high inhibitory activity of finasteride towards the 
human prostatic isozyme and its low toxicity 
allowed its use as a drug for the treatment of 
DHT dependent pathologies. Several clinical 
studies have demonstrated the efficacy of finas- 
teride in reducing the pathologic effects of 
benign prostatic hyperplasia (BPH) [2-4]. Finas- 
teride has been recently approved, and is now 
widely used, for the treatment of BPH. Other 
applications of this drug are now being studied, 
reserved 
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for the treatment of prostatic cancer [5,6] and 
male pattern baldness [7,8]. To support clinical 
studies it is therefore important o have a pre- 
cise, accurate and sensitive method to determi- 
nate finasteride in biological fluids. The methods 
developed since now are based on the use of 
HPLC coupled with an UV detector [9,10] or, 
recently, with an atmospheric pressure chemical 
ionization (APCI) tandem mass spectrometric 
(MS-MS) detector [11]. The sensitivity limit 
reached with the UV detector is 1 ng/ml and, 
due to the low wavelength of detection (210 nm), 
it results scarcely selective and requires an effi- 
cient and highly controlled sample preparation 
with a complex chromatographic system: finas- 
teride is purified from biological samples using a 
solid-phase extraction (SPE) CN column and 
analyzed with an HPLC system equipped with 
two coupled reversed-phase columns maintained 
at room temperature. The recent use of the mass 
spectrometric detector [11] has increased both 
the sensitivity (200 pg/ml) and the selectivity of 
the assay but, in the method described, the 
chromatographic system is still complex requir- 
ing a series of two reversed-phase columns main- 
tained at 70°C; moreover the MS-MS detector 
used is quite expensive and the complexity of the 
apparatus requires an accurate management to
perform a quantitative routinely assay. 
In this paper we describe a new method based 
on isotopic dilution gas chromatography-mass 
spectrometry for the determination f finasteride 
in human plasma using a GC-MS bench-top 
instrument. The present method results accurate, 
specific, sensible and reliable for a routinely 
determination of finasteride at picogram levels, 
and was applied to the determination of the 
pharmacokinetic profile of finasteride in plasma 
of five male volunteers treated with a 5-mg oral 
dose of the drug. 
2. Experimental 
2.1. Materials 
Finasteride was a kind gift of Merck Sharp & 
Dohme (Dr. ElisaLzth Stoner). The solvents 
employed for the synthesis were analytical grade 
and were purchased from Carlo Erba (Milan, 
Italy); all the reagents used for the synthesis 
were purchased from Sigma (St. Louis, MO, 
USA). The solvents employed for the purifica- 
tion procedure were analytical grade and were 
purchased from J.T. Baker (Phillipsburg, NJ, 
USA); columns used for the purification were 
SPE C18 (500 mg) IST Isolute (Mid Glamorgan, 
UK); GC capillary column used was an HPl-12 
m x 0.2 mm × 0.33 /zm obtained from Hewlett- 
Packard (Palo Alto, CA, USA). All analyses 
were performed using a Hewlett-Packard GC- 
MS system composed by a 5890 series II gas 
chromatograph equipped with a 5971A Mass 
Spectrometry Detector and a 7673A automatic 
injector. 
2.2. Methods 
Synthesis of deuterated internal standard 
5, 6,6-[e H3]finasteride (4) 
5,6,6-[2 H3]-3-Oxo-4-aza-androstane-17~- 
carboxylic acid (1). 
3-Oxo-4-aza-5-androstene-17fl-carboxylic acid 
(0.81 g, 2.55 mmol), prepared according to the 
procedure described by Rasmusson et al. [1,12] 
was stirred in 2H20 for 16 h at room tempera- 
ture and, after filtration, in CH3COO2H (12 ml) 
for 3 h. Then, the CH3COO2H solution was 
maintained for 48 h under 2H z (3 atm) at 60°C in 
the presence of Pt20 (0.12 g, 0.53 mmol). The 
solution was then filtered, evaporated and 
washed with water affording 5,6,6-[ H3]-3-oxo-4- 
aza-androstane-17fl-carboxylic acid (1) (90% 
yield, 2.29 mmol). 
5,6,6-[2 H~ ]-3 - Oxo-4-aza-androst- 1-ene- 17fl- 
carboxylic acid (2). 
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) 
(3.8 ml, 14.3 mmol) was added to a stirred 
suspension of 5,6,6-[2H3]-3-oxo-4-aza-andros - 
tane-17fl-carboxylic acid (1) (1.1 g, 3.41 mmol) 
and 2,3-dichloro-5,6-dicyano-l,4-benzoquinone 
(DDQ) (0.79 g, 3.48 mmol) in 11 ml of an- 
hydrous dioxane. The reaction mixture was 
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stirred at room temperature under N z for 4 h and 
then was refluxed for 18 h. The resulting dark 
red solution was poured into a mixture con- 
taining 20 ml of CH2C1 ~ and 5.3 ml of a 1% 
aqueous solution of sodium bisulphite. After 
vigorous stirring the mixture was filtered to 
eliminate the precipitated hydroquinone, the 
organic layer was separated, washed with 7 ml of 
2 M HC1 and dried over Na2SO 4. After removal 
of the solvent, the residue was washed with 
CH3CN and dried under vacuum affording 5,6,6- 
[ZH3]-3-oxo-4-aza-androst-l-ene-17fl-carboxylic 
acid (2) (70% yield, 2.39 mmol). 
S-2-Pyridyl-3-oxo- 4 aza-androst- 1 ene- 17~-thio- 
carboxylate (3). 
A solution of the 5,6,6-[ZH3]-3-oxo-4-aza-an - 
drost-l-ene-17/3-carboxylic ac d(2) (0.75 g, 2.34 
mmol), with triphenylphosphine (1.03 g, 4.67 
mmol) and 2,2'-dithiopyridine in 5 ml of toluene 
was stirred at room temperature for 6 h, then the 
solvent was evaporated under vacuum and the 
residue purified on a short silica gel column 
(70-230 mesh, 7 cm x 4 cm I.D.), using acetone- 
dichloromethane 1:1 (v:v) as eluent, to give S-2- 
pyridyl-3-oxo-4-aza-androst-l-ene-17/3-carboxy- 
late (3) (56% yield, 1.31 mmol). 
2 5,6,6-[ H3]-N-tert.-butyl-3-oxo-4-aza-5a-androst- 
1-ene-17fl-carboxamide (4). 
The S-2-pyridyl-3-oxo-4-aza-androst-l-ene- 
17/3-carboxylate (3) (0.25 g, 0.6 mmol) was 
suspended in 6 ml of anhydrous tetrahydrofuran 
with 0.5 ml (4.56 mmol) of tert.-butylamine; the 
suspension was stirred at room temperature for 
18 h, the solvent was evaporated under vacuum 
and the residue purified on a short silica gel 
column (70-230 mesh, 6 cm x 2.8 cm I.D.) using 
a mixture of acetone-dichloromethane 1:3 (v:v) 
as eluent, obtaining the 5,6,6-[2H3]-N-tert.-butyl - 
3-oxo-4-aza-5 a-androst-l-ene-17fl-carboxamide 
[2H3]finasteride ) (4) (43% yield, 0.26 mmol). 
The percentage of deuteration was obtained 
from selected ion monitoring (SIM) analysis 
(2H 3 focusing on the ions at m/z=375.2  = 
64.2%), m/z = 374.2 (eH2=30.96%), m/z  = 
373.2 (2H 1 = 4.57%), m/z  = 372.2 (2H 0 = 
0.45%). 
Instrumental conditions 
Analyses were performed using a 12 m x 0.2 
mm x 0.33/zm GC capillary column with a 100% 
methylsilicone phase. The temperature program 
was: 70°Cx 1 min; then 30°C/min to 200°C; 
200°C x 1 min; then 10°C/min to 280°C; 280°C x 
10 min; then 20°C/min to 300°C for 5 min. The 
transfer line temperature was 280°C. The carrier 
gas was helium with an inlet pressure of 35 KPa. 
In these conditions the retention time of finas- 
teride and its trideuterated analogue was 19.7 
min. Injections were performed in the splittless 
mode with a purge-off time of 1 min and an 
injector temperature of 280°C. SIM analyses 
were made acquiring the molecular ions at m/z  
372.2 and 375.2 for finasteride and 
[2H3]finasteride r spectively. 
Analytical method 
Extraction and purification of finasteride and 
I.S. from plasma samples were performed using 
SPE C j8 columns (500 mg). Columns were pre- 
washed with 2 x 3 ml of ethyl acetate and 3 ml of 
methanol, then conditioned with 3 ml of metha- 
nol and 3 ml of water. Plasma samples were 
diluted 1:5 with water and applied to columns, 
then columns were washed with 2 x 2.5 ml of 
bidistilled water, 3 ml of n-hexane and succes- 
sively with 3 x 3 ml of n-hexane-ethyl ether 
60:40 (this fraction contained testosterone and 
dihydrotestosterone). Finasteride was then eluted 
with 3 x 3 ml of ethyl acetate, the eluate was 
dried on a short column of anhydrous odium 
sulphate and then evaporated to dryness under 
nitrogen. Dry residues were dissolved in 15/~1 of 
n-heptane and 3 /~1 auto injected into the GG-  
MS instrument for the quantitative determina- 
tion. The amount of finasteride in plasma was 
determined by SIM analyses acquiring the molec- 
ular ions at m/z  372.2 for finasteride and m/z  
375.2 and [2H3]finasteride (I.S.). For each sample 
the peak-area ratio (PAR, area of finasteride 
peak versus area of [2H3]finasteride peak) was 
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measured and the amount of finasteride deter- 
mined from the calibration curve. 
Selectivity and linearity of the method 
Selectivity of the method was evaluated by 
analyzing blank samples and finasteride-free 
plasma samples. The calibration curve was made 
with eight points in the range 0-30 ng/ml of 
plasma and was obtained by adding the appro- 
priate amounts of finasteride and of the deuter- 
ated standard (5 ng) to plasma aliquots of 1 ml. 
Each point of the calibration curve was purified 
and analyzed as described and PAR were plotted 
versus finasteride concentration. A good linearity 
was obtained from 0 to 30 ng/ml (y = 0.214x- 
0.045; r = 0.997) 
Recovery 
Analytical recoveries were calculated as de- 
scribed by Dehennin [13]: identical samples of 1 
ml of plasma containing finasteride at the con- 
centration of 5 ng/ml were supplemented with 5 
ng of the deuterated internal standard (I.S.), 
either before or after the extraction and purifica- 
tion procedure. For each sample the peak-area 
ratio (PAR, area of finasteride peak versus area 
of [2H3]finasteride peak) was calculated and 
percentage of recovery was calculated as PAR 
(I.S. added before purification)/PAR (I.S. added 
after purification) × 100. 
Sensitivity 
Sensitivity limit of the instrument was evalu- 
ated by injection of decreasing amounts of finas- 
teride and calculating the signal-to-noise ratio 
(S/N); 50 pg of finasteride injected gave a S/N = 
6.4 (Fig. la). Sensitivity limit of the assay was 
evaluated analysing plasma samples (1 ml) at 
decreasing concentration of finasteride and cal- 
culating the S/N; samples at 250 pg/ml gave a 
S/N = 6.2 when 3 /zl of the 15 /zl final volume 
were injected (Fig. lb). 
Precision and accuracy of the method 
The precision and accuracy of the method 
were determined by replicate inter-day analyses 
(n = 5) of plasma samples (1 ml) at the following 
finasteride concentrations: 1, 5, 8 and 10 ng/ml. 
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Fig. 1. (a) Plots from computer of the signal corresponding to
the injection of 50 pg of finasteride (m/z = 372.2) and 50 pg 
of 2H3-finasteride (m/z 375.2). The S/N ratio is 6.4. (b) Plots 
from computer of the signal corresponding to a l-ml plasma 
sample of 250 pg/ml of finasteride (rn/z = 372.2) and 250 
pg/ml of 2H3-finasteride (m/z 375.2) processed according to 
the analytical method and injected in the GC-MS system 
(3-/zl injection of the 15-/xl final volume of heptane). S/N 
ratio is 6.2. 
Precision was evaluated by the percent coeffi- 
cient of variation (C.V.%) and accuracy was 
calculated as mean calculated concentration ver- 
sus nominal concentration (Table 1). 
Pharmacokinetic profile 
The pharmacokinetic profile was evaluated on 
five healthy male volunteers aged from 27 to 58 
and subjected to a single oral 5-mg dose of 
finasteride. Blood samples were collected before 
(time point 0) and 1, 2, 4, 8 and 24 h after oral 
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Table 1 
Precision and accuracy ofthe method" 
Nominal Concentration found Accuracy Precision 
concentration (mean +-S.D., n = 5) (%) (C.V., %) 
(ng/ml) (ng/ml) 
1.00 1.10 -+ 0.14 110 12.4 
5.00 5.34 _+ 0.31 106 5.81 
8.00 8.17 -+ 0.22 102 2.70 
10.00 9.95 _+ 0.40 99 4.00 
Precision and accuracy ofthe method were determined by
replicate inter-day analyses (n= 5) of plasma samples (1 
ml). Accuracy is calculated as: (mean calculated concen- 
tration/nominal concentration) × 100. 
administration. Immediately after collection the 
samples were centrifuged and plasma was stored 
at -20°C until analysis. Plasma aliquots (from 
0.3 to 1 ml) were diluted 1:5 (v/v) with bidistilled 
water and the internal standard (5 ng, in 50/~1 of 
ethanol) was added. Samples were equilibrated 
at 37°C for 1 h before analysis and then pro- 
cessed according to the above-described analyti- 
cal method. 
The kinetic parameters were calculated as 
follow [14]: Cma x was  the maximum concentra- 
tion of the pharmacokinetic profile and tma x was  
the time at which the maximum concentration 
was reached. The t~/2 was calculated as: 
0.693 
tl/2-- Kel 
were Kel is the elimination constant. The 
AUC0_24 was  calculated with the trapezoidal 
rule. 
3. Results and discussion 
3.1. Synthesis of the deuterated internal standard 
5,6,6-[2H3]Finasteride (4) was prepared from 
3-oxo-4-aza-5-androstene-17fl-carboxylic acid in
a four-step rocedure, as shown in Fig. 2. In the 
first step three deuterium atoms were introduced: 
first at position 6 by isotopic exchange in 2H20 
and CH3COOEH and then at position 5 and 6 by 
reduction with 2H 2 of the 5-6 double bound. The 
IR, IH-NMR, ~3C-NMR and MS spectra of deu- 
terated compound 1 were identical with the 
spectra reported for the hydrogenated compound 
[1,12]. The molecular ion in the MS spectrum at 
322 m/z, the absence in the ~3C-NMR spectrum 
of the C5 and C6 signals at 60.03 and 26.54 ppm, 
respectively, and the lack in the 1H-NMR spec- 
trum of the signal at 2.95 ppm corresponding to
the H-C5 hydrogen are consistent with the intro- 
duction of three deuterium atoms at the positions 
5,6,6. The conversion of the trideuterated com- 
pound (1) to 2H3-finasteride was made according 
to the reported procedure for the synthesis of 
finasteride. The procedure requires the intro- 
duction of a double bond in position 1-2, fol- 
lowed by activation of the carboxylic group and 
reaction with tert.-butylamine. The percentages 
of deuterated compounds obtained from selected 
ion monitoring (SIM) analysis were: [2H3]finas- 
teride 64.2%; [2H2]finasteride 30.96%; [2H 1 ]finas- 
teride 4.57% and non-deuterated finasteride 
0.45%. The high ratio of the trideuterated com- 
pound versus the non-deuterated one (2H0/ 
2H 3 = 0.007) allows an optimal use of [2H3]finas- 
teride as internal standard in an isotope dilution 
method. 
3.2. Analytical method 
This new method for the determination of 
finasteride in human plasma is the first one that 
uses a gas chromatography-mass spectrometry 
technique and it resulted very sensitive, accurate 
and precise owing to the use of a deuterated 
internal standard. 
The analytical procedure is simple and it can 
be easily automated for analysis of a large 
number of samples. The extraction and purifica- 
tion of finasteride from plasma was performed 
using only a single-step rocedure on a SPE-C18 
column. The choice of the washing solvents 
allowed the separation of T and DHT from 
finasteride which was eluted with ethyl acetate. 
After removal of ethyl acetate, a heptane solu- 
tion of the sample was injected directly into the 
GC-MS instrument without derivatization. The 
sensitivity of the method was at picogram level 
(250 pg/ml of plasma), analysing 1 ml of plasma 
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Fig. 2. Synthesis of [2H3]finasteride. (a) 2HzO 16 h, CH3COO2H 3 h; (b) 2H2, PtO 2, CH3COO2H, 3 atm, 60°C, 48 h; (c) BSTFA, 
DDQ, dioxane, 25°C, 4 h, then 101°C, 18 h; (d) 2,2'-dithiopyridine, PPh 3, toluene, 25°C, 6 h; (e) tert.-butylamine, THF, 25°C, 18 h. 
[2H3] is the trideuterated compound, [2H~] the dideuterated compound, [2H1] the monodeuterated compound and [2H0] the 
non-deuterated compound. 
and injecting 3/zl of the sample dissolved in 15 
#1 of heptane. The sensitivity of the method was 
increased to 80 pg/ml of plasma when 3 ml of 
plasma were used without any change in the 
isolation and purification procedure. The same 
sensitivity was also obtained by dissolving the 
dried eluate in 5 /zl of heptane and manually 
injecting 3 /zl of solution. However, the meth- 
odology giving the sensitivity of 250 pg/ml was 
sufficient for the analysis of plasma samples of 
the volunteers. Mean recovery for finasteride was 
90% (n = 6). No interferences were found deriv- 
ing from materials used or from endogenous 
compounds of plasma. Accuracy and precision 
shown in Table 1 attest a good reproducibility of
the analyses. 
This method has been applied to the determi- 
nation of the plasmatic pharmacokinetic profile 
of finasteride in five male volunteers treated with 
a single oral 5-mg dose of drug. The pharma- 
cokinetic profiles (illustrated in Fig. 3) and the 
kinetic parameters calculated (reported in Table 
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Fig. 3. Pharmacokinetic prof les of finasteride in plasma of five healthy male volunteers treated with a single 5-mg oral dose of the 
drug. 
2) are in excellent agreement with the pharma- 
cokinetic profile and the kinetic values obtained 
by other authors for the same dose of drug 
[10]. 
The purification procedure of the samples 
allows the separation of T and DHT from finas- 
teride and could be applied to the simultaneous 
determination of the drug and the two hormones 
by GC-MS. Some experiments are in progress in 
order to apply this methodology to clinical 
Table 2 
Pharmacokinetic parameters of finasteride in plasma 
Cma x Tin. x t,/2 AUCo 24 
(ng/ml) (h) (h) (ng h/ml)  
Volunteer 1 32.5 2 6.9 243.8 
Volunteer 2 23.7 4 11.5 333.2 
Volunteer 3 31.9 4 4.9 320.5 
Volunteer 4 39.4 2 4.9 305.0 
Volunteer 5 47.1 2 7.7 441.0 
GC-MS method 34.9 _+ 8.8 2.8 ÷ 1.1 7.2 ± 2.7 328.5 _+ 71.6 
mean _+ S.D. (n = 5) 
Reported values b 33.6 _+ 8.3 1.5 6.9 312.45 
Values calculated from the pharmacokinetic profile of five male healthy volunteers treated with a single oral 5-rag dose of 
finasteride. 
b These values were calculated from the pharmacokinetic profile described by Costanzer et al. [10]. 
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studies on patients affected by BPH under treat- 
ment with finasteride. 
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